Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged strategy to address neurological health, targeting both multiple sclerosis (MS) and alcohol misuse disorders. The biopharmaceutical company is developing Lucid-MS, an investigational therapy designed to protect and potentially restore the myelin sheath, and unbuzzd, a proprietary dietary supplement aimed at supporting alcohol metabolism. This dual approach reflects the company's commitment to tackling challenging neurodegenerative and metabolic conditions.
Lucid-MS is a patented new chemical entity that targets PAD2, an enzyme associated with myelin degradation. Unlike traditional MS treatments that primarily modulate the immune system, Lucid-MS aims to directly protect and reverse myelin damage. Preclinical models have shown that Lucid-MS can prevent and reverse myelin degradation, the underlying mechanism of MS. The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 trial. Additionally, Quantum BioPharma is supporting the development of Lucid-MS through an imaging collaboration with Massachusetts General Hospital, which could provide crucial insights into the drug's effects on myelin integrity.
In parallel, Quantum BioPharma has developed unbuzzd, a dietary supplement designed to reduce acute intoxication and hangover effects. The company cites results from a randomized, placebo-controlled clinical trial that demonstrated unbuzzd's efficacy in supporting alcohol metabolism. Quantum BioPharma invented unbuzzd and spun out its over-the-counter (OTC) version to Unbuzzd Wellness Inc. (UWI), a company led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI (as of March 31, 2026) and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The company's focus on both MS and alcohol misuse disorders underscores a broader mission to address conditions that significantly impact quality of life. MS affects millions worldwide, and current treatments often have limitations in halting disease progression. By targeting myelin repair, Lucid-MS could offer a novel therapeutic approach. Meanwhile, alcohol misuse is a widespread public health issue, and unbuzzd may provide a supportive tool for individuals seeking to mitigate the immediate effects of alcohol consumption.
Quantum BioPharma's progress on both fronts is notable. The IND submission for Lucid-MS is a critical step toward clinical validation, and the collaboration with Massachusetts General Hospital adds credibility to the imaging-based assessment of myelin changes. For unbuzzd, the clinical trial results provide evidence of its potential benefits, and the royalty arrangement with UWI offers a revenue stream that could support further research and development.
Investors and stakeholders are closely watching these developments, as they could position Quantum BioPharma as a key player in neurology and metabolic health. The company's ability to advance both programs simultaneously demonstrates a strategic approach to building a diversified portfolio of innovative assets. As Quantum BioPharma continues to progress its pipeline, the outcomes of the Lucid-MS Phase 2 trial and the market performance of unbuzzd will be pivotal in determining the company's trajectory.
